programs

NABH INTEGRATES FOGSI’S MATERNAL HEALTH STANDARDS ACROSS ITS CERTIFICATION PROGRAMSNABH INTEGRATES FOGSI’S MATERNAL HEALTH STANDARDS ACROSS ITS CERTIFICATION PROGRAMS

NABH INTEGRATES FOGSI’S MATERNAL HEALTH STANDARDS ACROSS ITS CERTIFICATION PROGRAMS

The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative's 20 quality standards across NABH's…

5 months ago
Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

November 08, 2024 10:00 ET | Source: Medicenna Therapeutics Corp.    MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT…

5 months ago
Show previous Posts